Inferring Alzheimer's disease pathologic traits from clinical measures in living 1 2 adults 3 4 Author(s): 5 Jingjing **Yang**, PhD¹*; Xizhu **Liu**, BS²; Shahram **Oveisgharan**, MD³; Andrea R. 6 Zammit, PhD³; Sukriti Nag, MD, PhD,³ David A Bennett, MD³; Aron S Buchman, MD³ 7 8 9 10 Affiliation Information for All Authors: 1. Center for Computational and Quantitative Genetics. Department of Human Genetics. 11 12 Emory University School of Medicine, 615 Michael St, Atlanta, GA, 30322, USA; 13 2. Department of Biostatistics, Yale University School of Public Health, 60 College St. 14 New Haven, CT, 06510, USA; 15 3. Rush Alzheimer's Disease Center, Rush University Medicine Center, 1620 W Harrison St, Chicago, IL, 60612, USA. 16 17 18 19 20 **Corresponding Author:** 21 * Jingjing Yang Address: Department of Human Genetics, Emory University School of Medicine, 615 22 23 Michael Street, Suite 305K, Atlanta, GA, 30322, USA 24 Email: jingjing.yang@emory.edu 25 Phone: 404-727-3481 26 27

29 ABSTRACT

30	Background: Alzheimer's disease neuropathologic changes (AD-NC) are important for
31	identify people with high risk for AD dementia (ADD) and subtyping ADD.
32	Objective: Develop imputation models based on clinical measures to infer AD-NC.
33	Methods: We used penalized generalized linear regression to train imputation models
34	for four AD-NC traits (amyloid- β , tangles, global AD pathology, and pathologic AD) in
35	Rush Memory and Aging Project decedents, using clinical measures at the last visit
36	prior to death as predictors. We validated these models by inferring AD-NC traits with
37	clinical measures at the last visit prior to death for independent Religious Orders Study
38	(ROS) decedents. We inferred baseline AD-NC traits for all ROS participants at study
39	entry, and then tested if inferred AD-NC traits at study entry predicted incident ADD and
40	postmortem pathologic AD.
40 41	postmortem pathologic AD. Results: Inferred AD-NC traits at the last visit prior to death were related to postmortem
40 41 42	postmortem pathologic AD. Results: Inferred AD-NC traits at the last visit prior to death were related to postmortem measures with R^2 =(0.188,0.316,0.262) respectively for amyloid- β , tangles, and global
40 41 42 43	postmortem pathologic AD. Results: Inferred AD-NC traits at the last visit prior to death were related to postmortem measures with R^2 =(0.188,0.316,0.262) respectively for amyloid- β , tangles, and global AD pathology, and prediction Area Under the receiver operating characteristic Curve
 40 41 42 43 44 	postmortem pathologic AD. Results: Inferred AD-NC traits at the last visit prior to death were related to postmortem measures with <i>R</i> ² =(0.188,0.316,0.262) respectively for amyloid- <i>β</i> , tangles, and global AD pathology, and prediction Area Under the receiver operating characteristic Curve (AUC) 0.765 for pathologic AD. Inferred baseline levels of all four AD-NC traits
 40 41 42 43 44 45 	postmortem pathologic AD. Results: Inferred AD-NC traits at the last visit prior to death were related to postmortem measures with <i>R</i> ² =(0.188,0.316,0.262) respectively for amyloid-β, tangles, and global AD pathology, and prediction Area Under the receiver operating characteristic Curve (AUC) 0.765 for pathologic AD. Inferred baseline levels of all four AD-NC traits predicted ADD. The strongest prediction was obtained by the inferred baseline
 40 41 42 43 44 45 46 	postmortem pathologic AD. Results: Inferred AD-NC traits at the last visit prior to death were related to postmortem measures with R ² =(0.188,0.316,0.262) respectively for amyloid-β, tangles, and global AD pathology, and prediction Area Under the receiver operating characteristic Curve (AUC) 0.765 for pathologic AD. Inferred baseline levels of all four AD-NC traits predicted ADD. The strongest prediction was obtained by the inferred baseline probabilities of pathologic AD with AUC=(0.919,0.896) for predicting the development of
 40 41 42 43 44 45 46 47 	postmortem pathologic AD. Results: Inferred AD-NC traits at the last visit prior to death were related to postmortem measures with R ² =(0.188,0.316,0.262) respectively for amyloid-β, tangles, and global AD pathology, and prediction Area Under the receiver operating characteristic Curve (AUC) 0.765 for pathologic AD. Inferred baseline levels of all four AD-NC traits predicted ADD. The strongest prediction was obtained by the inferred baseline Probabilities of pathologic AD with AUC=(0.919,0.896) for predicting the development of ADD in 3 and 5 years from baseline. The inferred baseline levels of all four AD-NC traits
 40 41 42 43 44 45 46 47 48 	postmortem pathologic AD. Results: Inferred AD-NC traits at the last visit prior to death were related to postmortem measures with R ² =(0.188,0.316,0.262) respectively for amyloid-β, tangles, and global AD pathology, and prediction Area Under the receiver operating characteristic Curve (AUC) 0.765 for pathologic AD. Inferred baseline levels of all four AD-NC traits predicted ADD. The strongest prediction was obtained by the inferred baseline probabilities of pathologic AD with AUC=(0.919,0.896) for predicting the development of ADD in 3 and 5 years from baseline. The inferred baseline levels of all four AD-NC traits

50 **Conclusion:** Inferred AD-NC traits based on clinical measures may provide effective

51 AD biomarkers that can estimate the burden of AD-NC traits in aging adults.

52

53 **KEYWORDS:** Alzheimer's disease; Computational modeling; Alzheimer's disease

54 neurologic change; Dementia; Pathology

J. Yang 4

55 **INTRODUCTION**

56 The accumulation of Alzheimer's disease neuropathologic changes (AD-NC). 57 such as amyloid- β and intracellular neurofibrillary tangles, underlying Alzheimer's 58 disease dementia (ADD) has been observed even during the initial stages of ADD when 59 cognition is normal [1]. Higher levels of AD-NC during the early stages of ADD have 60 been shown to be associated with an increased risk of ADD [2-6]. Separate therapies have been developed for targeting the peptide amyloid- β in extracellular amyloid 61 62 plagues and the protein tau in intracellular neurofibrillary tangles [7-9]. Yet, conventional prediction models identifying adults at risk for clinical ADD do not inform on which AD-63 64 NC traits underlie the risk of ADD. Thus, procedures that can accurately infer elevated 65 levels of AD-NC traits in living adults with normal cognition have the potential to facilitate early targeted treatments [10-17]. 66

67 Direct measures of brain AD-NC traits can only be obtained at autopsy. Recent 68 efforts to quantify AD-NC during life have focused on identifying biomarkers of AD-NC traits by using brain imaging or fluid AD biomarkers [18-20]. Recent work comparing tau 69 70 and amyloid positron emission tomography (PET) brain imaging measures to indices 71 measured at autopsy, suggests that current imaging may not reliably detect the early 72 stages of AD pathology [21, 22]. Particularly, brain imaging and CSF biomarkers are not 73 widely available due to their costs, invasiveness, and difficultly to deploy at scale. 74 Studies focusing on serum biomarkers have advanced rapidly in recent years, yet the 75 field has not converged on specific biomarkers that can be employed in the general population [23-27]. 76

J. Yang 5

77	Rapid advances in machine learning methods such as penalized generalized
78	linear regression [28] have been employed to impute missing data or infer data that are
79	difficult to be measured directly in biomedical research fields [29-34]. Similarly, the
80	penalized generalized linear regression method could be deployed to develop
81	imputation models based on clinical measures in older adults to infer levels of AD-NC
82	traits. Such imputation models learn the predictive information of postmortem AD-NC
83	traits like tangles from clinical measures obtained prior to death in decedents
84	undergoing autopsy. The imputation model works by mathematically "explaining" the
85	variation of observed AD-NC traits measured in decedents by their equivalence of
86	weighted linear combinations of predictive clinical measures. Once imputation models
87	developed for AD-NC traits are validated in an independent cohort, they can be applied
88	to any older adults with similar clinical measures to infer AD-NC traits.

89 Comprehensive clinical and postmortem data are necessary to develop and 90 validate imputation models for AD-NC traits. This multi-stage study leveraged clinical 91 and postmortem data from two harmonized, independent, longitudinal prospective 92 cohort studies — Rush Memory and Aging Project (MAP) and the Religious Orders 93 Study (ROS) [35]. First, we trained imputation models for four AD-NC traits (amyloid- β , 94 tangles, global AD pathology, and pathologic AD diagnosis) by applying the penalized 95 generalized linear regression method to clinical measures obtained at the last visit 96 before death and postmortem AD-NC indices measured at autopsy in MAP decedents. 97 Second, we validated the imputation models in a second independent cohort (ROS) 98 which collected the same clinical and postmortem AD-NC traits. Third, we applied the 99 imputation models to clinical measures collected in adults without dementia at study

J. Yang 6

100	entry to infer baseline levels of AD-NC traits that were on average about eight years
101	before death for decedents (or before last visit for living participants). We demonstrated
102	the efficacy of these interfered baseline AD-NC traits as effective AD biomarkers, by
103	showing their predictivity of future clinical ADD and discrimination of postmortem
104	pathologic AD.
105	
106	MATERIALS AND METHODS
107	Participants
108	Participants were community-dwelling older adults enrolled without known dementia and
109	with at least two annual visits in one of two ongoing longitudinal prospective cohort
110	studies of chronic conditions of aging — MAP (n=1179 with \sim 500 autopsied) and ROS
111	(n=1103 with ~600 autopsied). Both cohorts employed a harmonized data collection
112	battery administered by the same research assistants facilitating joint analyses. For this
113	study, we included adults without clinical evidence of dementia at enrollment with at
114	least two annual follow-up cognitive assessments. At study entry, 1742 adults had no
115	cognitive impairment (NCI) and 540 adults had mild cognitive impairment (MCI) (Table
116	S1). The duration of annual follow-up for participants ranged from 2 to 26 years, with an
117	average follow-up of 8 years (SD, 5.42 years) [Fig S1; Tables S1-S2].
118	

119 Assessment of AD-NC Traits

After the death of ROS/MAP participants, their brains were removed and
 hemisected following the standard procedure, as previously described [35]. Tissue

J. Yang 7

122	blocks were dissected from predetermined regions and used for postmortem diagnosis
123	of pathologic AD. Structured autopsy collected indices of AD/ADRD pathologies that
124	were collected blinded to all prior clinical and cognitive data. This study focuses on the
125	development of imputation models to infer the following four AD-NC traits that were
126	measured in autopsied decedents (Table S2).

Amyloid-β was labeled with an N-terminus–directed monoclonal antibody (10D5;
 Elan, Dublin, Ireland; 1:1,000). Immunohistochemistry was performed as previously
 described using diaminobenzidine as the reporter, with 2.5% nickel sulfate to enhance
 immunoreaction product contrast.

131 **PHFtau (Tangles)** was labeled with an antibody specific for phosphorylated tau 132 (AT8; Innogenetics, San Ramon, CA; 1:1,000). Amyloid-β load and tangles were 133 guantified in 8 brain regions (anterior cingulate cortex, superior frontal cortex, mid 134 frontal cortex, inferior temporal cortex, hippocampus, entorhinal cortex, angular 135 gyrus/supramarginal gyrus, and calcarine cortex). Overall amyloid- β load was calculated 136 through averaging mean percent area of amyloid- β deposition per region, across 137 multiple brain regions. Tangles densities were derived by averaging tangles densities 138 across corresponding brain regions. Measures of amyloid- β and tangles were further 139 square-root transformed to improve their asymptotic normality as previously reported 140 [36, 37].

Global AD Pathology: A modified Bielschowsky silver stain was used to
visualize neuritic plaques, diffuse plaques, and neurofibrillary tangles in five cortical
areas (hippocampus, entorhinal, midfrontal, middle temporal, and inferior parietal).
Neuritic and diffuse plaques, and neurofibrillary tangles were counted in the region that

J. Yang 8

145	appeared to have the maximum density of each pathology as previously described. A
146	standardized score was created for each neuropathology in each region by dividing the
147	raw count by the standard deviation of the mean for the same neuropathology in the
148	same region. This standardization procedure puts the pathologic indices on a relatively
149	common scale. A summary global AD pathology score was made based on the average
150	of the greatest density of neuritic plaques, diffuse plaques, and neurofibrillary tangles in
151	one mm² [38, 39]

Pathologic Diagnosis of AD: The National Institute on Aging-Reagan criteria
were used with intermediate and high likelihood cases indicating a pathologic diagnosis
of AD, which is a binary indicator with value 1 denoting the present of pathologic AD
and 0 denoting the absent of pathologic AD [40].

156

157 Assessment of Composite Cognition Score and Cognitive Status

A structured cognitive assessment was administered annually. The neuropsychological battery included 19 tests that assessed five cognitive abilities (episodic memory, semantic memory, working memory, visuospatial ability/perceptual orientation, and perceptual speed). Raw test scores were standardized for each test using baseline means and standard deviations (SDs) of both cohorts; the resulting Zscores were then averaged across these cognitive tests to derive a single summary composite cognition score as described in prior publications [35, 41].

165 Cognitive diagnoses were made in a three-step process. Cognitive testing was 166 scored by a computer program and the results were reviewed by a neuropsychologist to 167 diagnose cognitive impairment. Then participants were evaluated by a physician who

J. Yang 9

168	used available cognitive and clinical data to classify cognitive status at each annual
169	visit. Dementia required meaningful decline in cognitive function with impairment in
170	multiple areas of cognition, and AD required dementia and progressive loss of episodic
171	memory. Individuals with cognitive impairment who did not meet dementia criteria were
172	diagnosed with mild cognitive impairment (MCI). Individuals without dementia or MCI
173	were classified as having no cognitive impairment (NCI). Clinical diagnosis of cognitive
174	status was based on published criteria [42-44]. Participants with dementia due to
175	primary cause other than AD are excluded in this study. At the time of death, select
176	clinical data from the entire study were reviewed by a neurologist, blinded to
177	postmortem data, to render a final cognitive status diagnosis[35].

178

179 **Clinical Covariates**

180 Diverse clinical measures were used to develop imputation models for four AD-181 NC traits. **Table S3** shows the complete list and groupings of the 57 clinical measures 182 examined in this study, including both cross-sectional and longitudinal variables. Cross-183 sectional clinical measures were collected only once for each participant, such as sex, 184 education, and APOE genotype. Longitudinal clinical measures were collected each 185 time during participants' annual visits. Baseline clinical characteristics are provided in 186 Tables S2, S4, and S5 and a heat map (Fig S2) is included to show the inter-187 correlations of the clinical variables examined in this study. The measures analyzed in 188 this study were selected after excluding cross-sectional variables with a high proportion 189 of missing values and those that were highly correlated with other selected clinical 190 measures (correlation>0.95). Samples with missing values in the selected cross-

191	sectional clinical measures were excluded. Missing values of longitudinal clinical
192	measures were assumed to be missed at random and were imputed from the measured
193	values at the nearest visit of the same participant, by using the "fill(.direction = "up")"
194	function from R library "tidyr". That is, if a participant had a missing value at last visit for
195	a longitudinal variable, the missing value would be imputed as the measured value of
196	this variable in this participant's nearest previous visit with collected measurement. The
197	percentage of missing data (i.e., missing rate) in the longitudinal clinical measurements
198	at last visit and study baseline were presented in Fig, S3. The number of samples that
199	were actually used in the analyses are presented in Tables S6 , and S7 .
200	
201	Analytic Approach
202	A multi-stage analytic approach was employed to develop, validate, and
203	demonstrate the effectiveness of the inferred the levels of four AD-NC traits at study
204	entry as potential AD biomarkers.
205	
206	Developing imputation models to infer AD-NC traits
207	Stage 1. Training imputation models.
208	We trained an imputation model for each of the four AD-NC traits using 57
209	clinical variables obtained in MAP participants at the last visit before death as
210	predictors, by using the generalized linear regression model with Elastic-Net penalty
211	(GLM-EN) [45] (Fig 1A). Only MAP decedents with autopsy were used for developing
212	imputation models, because profiled AD-NC traits were required. By using the GLM-EN

213	method, variable selection was implemented and potential collinearity among clinical
214	variables was accounted for during model training. Since the Elastic-Net penalty is a
215	linear combination of L1 (i.e. LASSO) [46] and L2 (i.e., Ridge) [47] penalties on the
216	coefficients of clinical variables, variable selection are handled by the L1 penalty (i.e.,
217	penalizing the L1 norm of the coefficient vector) while potential collinearity is accounted
218	for by the L2 penalty (i.e., penalizing the L2 norm of the coefficient vector). Ten-fold
219	cross validation was used during model training to select Elastic-Net penalty parameters
220	(i.e., the proportions of L1 and L2 penalty) to ensure optimal imputation accuracy.
221	Stage 2. Validating imputation models in a second independent cohort.
222	Next, we validated the performance of the imputation models developed to infer
223	four AD-NC traits using clinical variables measured at the last visit proximate to death in
224	a second independent cohort with ROS decedents (Fig 1A). Prediction R^2 , the squared
225	correlation between inferred and measured values, was used for assessing imputation
226	accuracy for continuous AD-NC traits. Prediction accuracy for the dichotomous
227	pathologic AD diagnosis was evaluated by the predicted area under curve (AUC) values
228	of receiver operating characteristic curve (ROC) [48].
229	Stage 3. Infer AD-NC traits at study entry and test their effectiveness as AD biomarkers
230	Once imputation models are trained and validated, they can be applied to any
231	living adult with the same clinical variables measured. So, to illustrate the use of these
232	imputation models, we applied these validated models to the clinical data obtained from
233	ROS participants at study entry (i.e., baseline that was on average of eight years before
234	death or last follow-up visit) to infer baseline AD-NC traits (Fig 1B). Scatter plots and
235	ROC curves were used to evaluate the consistency between inferred AD-NC traits at

J. Yang 12

baseline and the corresponding measured postmortem AD-NC traits profiled at autopsy
in ROS decedents. Then we examined the effectiveness of inferred AD-NC traits as
potential AD biomarkers through two complementary analyses, one for evaluating the
predictivity for incident ADD by Cox proportional hazard model (Stage 3A) and the other
one for evaluating the discrimination of postmortem pathologic AD (Stage 3B).

241 Stage 3A. We fitted Cox proportional hazard models using covariates of age, 242 sex, education, and a single inferred baseline AD-NC trait in MAP cohort for predicting 243 incident ADD. Then we evaluated the performance of the Cox models for predicting 244 incident ADD in year 3 and year 5 from baseline in ROS cohort (Fig S4). Our fitted Cox 245 proportional hazard risk prediction models [49-51] also accounted for the competing risk 246 of death. The annual cognitive status diagnosis and the follow up year were used to 247 identify the first occurrence of ADD. For each participant, the year of enrollment is 248 considered as baseline (time 0), the year of first diagnosis of ADD is considered as the 249 time when the event occurs (incident ADD), and the last visit of participants without the 250 considered event during all follow-ups is considered as the right censored time for living 251 participants or the time of death for dead participants without ADD. Sample size 252 distributions with respect to cognitive status at baseline and the cognition event types 253 are shown in **Tables S1**. All Cox models were trained using data from MAP participants 254 (both living and deceased) and tested with data from ROS participants (both living and 255 deceased).

For fitting and testing Cox models for predicting incident ADD, we first used all individuals without dementia at baseline, and then fitted and tested another set of Cox models by using only individuals with NCI at baseline. For each set of Cox models fitted

J. Yang 13

by using MAP participants, we calculated model accuracy (AUC) for predicting incident
ADD in year 3 and year 5 from baseline.

261 Since Cox models provide a continuous risk score for incident ADD, by selecting 262 a risk score threshold corresponding to ~80% specificity (the proportion of correctly 263 predicted non-ADD in test ROS participant's, i.e., 1 – false positive fraction), we could 264 calculate sensitivity (the proportion of true positive predictions in all test cases, i.e., true 265 positive fraction), and the overall classification accuracy (the proportion of true 266 discrimination of ADD in all test samples). Samples with risk scores greater than the 267 selected threshold were considered to develop ADD and less than the threshold as not 268 developing ADD in a specific year. That is, given the known ADD status of participants 269 in year 3 and year 5 from baseline, we can compare the predicted risk of incident ADD 270 to the actual incident ADD status to calculate the overall classification accuracy. 271 specificity, and sensitivity. Also, the sensitivity and specificity corresponding to a 272 selected risk score threshold reflect risk model performance at one point in the ROC 273 plots.

We also sequentially added the other three inferred baseline AD-NC traits into the Cox model, in addition of covariates of age, sex, education, and inferred baseline amyloid- β , and examined the prediction performance of these models.

277 Stage 3B. We examined the discrimination of inferred baseline levels of AD-NC 278 traits with respect to postmortem pathologic AD diagnosis (**Fig 1B**). Boxplots and two-279 sample t-tests were used to evaluate the discrimination of postmortem pathologic AD by 280 inferred baseline AD-NC traits. Only ROS decedents with profiled pathologic AD 281 diagnoses were use in this discrimination analysis.

J. Yang 14

282

283 **RESULTS**

284 **Developed Imputation Models for Inferring AD-NC Traits**

285 Imputation models were trained to infer AD-NC traits by applying the GLM-EN 286 method using clinical measures in MAP decedents at their last visit before death as 287 predictors. Selected predictive clinical measures with standardized effect sizes 288 |beta| >0.01 estimated by the imputation models are shown in Fig 2. Composite 289 cognition score and APOE E4 allele were the strongest predictors that were selected for 290 all four AD-NC traits. Yet, Fig 2 also illustrates that varied non-cognitive clinical 291 measures including motor function such as motor gait and dexterity, health conditions 292 such as anxiety and hypertension, and medications such as lipid lowering and anti-293 inflammatory medications were also selected. The effect size for motor gait was nearly 294 as strong as APOE for tangles, amyloid-beta, and global AD pathology. 295 These estimated effect sizes of selected clinical measure predictors in the 296 imputation models are used as weights to construct weighted sum with clinical 297 measurements to infer AD-NC trait levels. So, while all four AD-NC traits are related and 298 may share composite cognition score and APOE E4 allele as important predictors, the 299 different sets of selected predictors by these four imputation models highlight that 300 mathematically different combinations of clinical measures with different estimated 301 effect sizes are necessary to best capture unique features of these inter-related AD-NC 302 traits.

J. Yang 15

304 Validation of Imputation Models for Inferring AD-NC Traits

305 To validate the imputation models developed in MAP decedents, we applied the 306 imputation models to clinical measures obtained at the last visit prior to death for 307 decedents in a second independent ROS cohort to infer their levels of four AD-NC traits. 308 Scatter plots illustrate the correlations between the inferred levels of the three 309 continuous AD-NC traits and their corresponding indices measured at autopsy (Fig S5, **A-C).** The prediction R^2 was 0.188 for amyloid- β , 0.316 for tangles, and 0.262 for global 310 311 AD pathology (**Table S8**). An ROC plot (with AUC=0.765) illustrates the consistency 312 between the inferred probabilities of pathologic AD based on clinical measures obtained 313 at last visit before death versus the profiled pathologic AD status by autopsy (Fig S5D; 314 Table S8). As would be expected for effective AD biomarkers, all four inferred AD-NC 315 traits discriminated profiled pathologic AD at autopsy, with two-sample test P values < 316 10^{-28} (Box plots in **Fig S5**; **Table S8**). Together these results in a second independent 317 cohort validated the accuracy of the imputation models developed in MAP for all four 318 AD-NC traits.

319

320 Inferred Baseline AD-NC Traits Predicted Incident ADD

The imputation models were developed and validated using clinical measures at the last visit prior to death in MAP and ROS decedents. In further analyses we examined the effectiveness of inferred baseline AD-NC traits at study entry as AD biomarkers. To infer baseline levels of four AD-NC traits at study entry, we applied the validated imputation models to clinical data collected at baseline in all ROS participants (n=1103; both living and decedents), an average of 8 years before death for decedents

J. Yang 16

327	(or last follow-up for living participants) (Fig 1B). Scatter plots of the three continuous
328	AD-NC traits and an ROC plot of the binary pathologic AD illustrate the correlation
329	between the inferred baseline versus the profiled AD-NC traits by autopsy (Fig S6).
330	Although the correlations were lower than the inferred AD-NC traits at last visit before
331	death (Fig S5), the following analyses with Cox models still demonstrated the
332	predictivity of the inferred baseline AD-NC traits for predicting incident ADD.
333	We employed separate Cox models that considered covariates age, sex,
334	education, and each one of the four inferred baseline AD-NC traits to examine the
335	predictivity for incident ADD (Fig 3). Coefficient estimates of the inferred baseline AD-
336	NC traits in these Cox models were provided along with the corresponding p-values in
337	Table S9. All inferred baseline AD-NC traits were strongly associated with incident
338	ADD, with p-values $< 10^{-30}$ in Cox models predicting incident ADD for adults without
339	dementia at baseline, and p-values $< 10^{-5}$ in Cox models for predicting incident ADD
340	from adults with NCI at baseline.
341	For all four AD-NC traits, model performance was higher in Year 3 (AUC ranging
342	in 0.861 – 0.919) versus Year 5 (AUC ranging in 0.842 – 0.896) from baseline (Fig 3,
343	Upper Row), for predicting incident ADD for adults without dementia at baseline. Of the
344	four AD-NC traits, inferred baseline probabilities of pathologic AD had the highest
345	predictivity (AUC 0.919 in Year 3; AUC 0.896 in Year 5) for incident ADD from adults
346	without dementia at baseline. Similar results were observed when we restricted the
347	analyses to the prediction of incident ADD in individuals with NCI at baseline (Fig 3,

348 Lower Row).

J. Yang 17

 calculated sensitivity and accuracy based on the prediction results for all of the Cox models (Table 1). Inferred baseline probabilities of pathologic AD also had the higher accuracy rates (80%) and sensitivity for predicting incident ADD in Year 3 (0.911) and Year 5 (0.829) from baseline (Table 1), compared to the other AD-NC traits. 	349	By selecting a risk score threshold corresponding the ~80% specificity, we
 models (Table 1). Inferred baseline probabilities of pathologic AD also had the higher accuracy rates (80%) and sensitivity for predicting incident ADD in Year 3 (0.911) and Year 5 (0.829) from baseline (Table 1), compared to the other AD-NC traits. 	350	calculated sensitivity and accuracy based on the prediction results for all of the Cox
 accuracy rates (80%) and sensitivity for predicting incident ADD in Year 3 (0.911) and Year 5 (0.829) from baseline (Table 1), compared to the other AD-NC traits. 	351	models (Table 1). Inferred baseline probabilities of pathologic AD also had the highest
Year 5 (0.829) from baseline (Table 1), compared to the other AD-NC traits.	352	accuracy rates (80%) and sensitivity for predicting incident ADD in Year 3 (0.911) and
	353	Year 5 (0.829) from baseline (Table 1), compared to the other AD-NC traits.

In further analyses, we examined if adding covariates of additional inferred baseline AD-NC traits in a single Cox model would improve the prediction accuracy for incident ADD. As shown in **Fig S7 (Upper Row)**, we observed slightly improved AUC for prediction of incident ADD in adults without dementia, when we sequentially added each of the four AD-NC traits. Yet, modeling all four AD-NC traits together did not yield better results than using inferred probabilities of pathologic AD alone (**Last Column of Fig3 versus Fig S7**).

Sequentially adding the inferred baseline levels of three continuous AD-NC traits (amyloid- β , tangles, and global AD pathology) in a single Cox model did not improve the prediction of incident ADD for adults with baseline NCI (**Fig S7, Lower Row**). Although adding the inferred baseline levels of the probabilities of pathologic AD improved the prediction accuracy of incident ADD for adults with baseline NCI, but the prediction accuracy was comparable as using the inferred baseline levels of the probabilities of pathologic AD alone (**Last Column of Fig3 versus Fig S7**).

368

369 Inferred Baseline AD-NC Traits Discriminated Postmortem Pathologic AD

370 By examining if the inferred baseline AD-NC traits would discriminate

371 postmortem pathologic AD diagnosis, we presented boxplots of the inferred baseline

J. Yang 18

372	AD-NC traits of ROS decedents with respect to their postmortem pathologic AD
373	diagnosis by autopsy in Fig 4. By two-sample t-tests, we showed that all four inferred
374	baseline AD-NC traits discriminated individuals with postmortem pathologic AD
375	diagnosis by autopsy, with significant p-values $< 1.4 \times 10^{-10}$.
376	
377	DISCUSSION
378	This study applied the machine learning GLM-EN methods to clinical
379	measurements and postmortem indices of four AD-NC traits (amyloid- β , tangles, global
380	AD pathology, and pathologic AD) obtained from the same older adults to develop
381	imputation models that could be used to infer levels of four AD-NC traits based on
382	clinical measurements. We validated these imputation models of AD-NC traits in a
383	second independent cohort of older adults that collected similar clinical and postmortem
384	indices. We applied the validated imputation models to clinical measures obtained at
385	study entry to infer baseline AD-NC traits in adults about an average of eight years
386	before death (decedents) or their last follow-up visit (living participants).
387	Adults without dementia at study entry who had higher baseline levels of inferred
388	AD-NC traits had a higher risk of developing incident ADD during follow-up years and
389	they also had a higher risk of having postmortem pathologic AD. These data suggest
390	that inferred levels of AD-NC traits based on clinical measures may provide a low cost,

non-invasive effective AD biomarker that can estimate the burden of AD-NC traits

way to monitor the clinical course of the accumulation of AD-NC traits underlying

Alzheimer's disease, improve the homogeneity of clinical trials and catalyze early

during the chronic course of Alzheimer's disease. Inferred AD-NC traits may provide a

391

392

393

J. Yang 19

- targeted treatments to prevent the development of ADD in aging adults. Further studies
 to validate longitudinal inferred AD-NC traits will be needed.
- 397

398 Novelty of this Study

399 Currently AD-NC traits in brain can only be measured at autopsy. Recent work has 400 focused on identifying effective AD biomarkers that can be used to assess levels of AD-401 NC traits in living adults, especially during early stages of AD when cognition is still normal. 402 There are many prior studies that have examined the associations of clinical measures. 403 such as APOE E4 allele, age, and cognitive measures, with future cognitive status or with 404 different AD/ADRD indices measured at autopsy including the postmortem diagnosis of 405 pathologic AD. Yet, it is important to note that the aim of these prior studies was not to 406 infer levels of the different AD-NC traits examined in this study, nor to test their 407 effectiveness as AD biomarkers [52-56].

408 Brain imaging studies of AD-NC traits have tried to employ serial imaging or CSF 409 fluid biomarkers as proxies to obtain measures of AD-NC traits in brains to assess the 410 accumulation of amyloid- β and tangles in early stages of Alzheimer's disease [18-20]. 411 Recent work that compared tau and amyloid PET brain imaging to AD indices measured 412 at autopsy, suggests that current imaging may not reliably detect the early stages of AD 413 pathology [21, 22]. Yet, the expense and limited availability of brain imaging and the 414 invasiveness of obtaining CSF biomarkers make them difficult to be deployed at scale for 415 the general population. This study fills this gap by employing machine learning methods 416 that could be used to mathematically infer an AD-NC trait like "tangles" and estimate its 417 burden at any time point prior to death in any adult with the requisite clinical measures.

J. Yang 20

Obtaining structured autopsy and diverse clinical measures during annual followups, especially within a year prior of death, in large numbers of older adults is difficult. Thus, it is novel to have two large cohorts like MAP or ROS with the same clinical and postmortem indices of AD-NC traits that can be leveraged to develop imputation models in one cohort and validate these imputation models in a second independent sample of older adults. The rarity of these resources may explain in part the paucity of previous studies trying to infer AD-NC traits based on clinical measurements alone.

Another novel feature of this study is that we provide evidence that inferred baseline AD-NC traits on average 8 years before death for decedents (or before last visit for living participants) may be used as effective AD biomarkers as they predicted incident ADD and discriminated postmortem pathologic AD. That is, this study provides novel data demonstrating the feasibility and effectiveness of developing imputation models to infer AD-NC traits from clinical measures alone.

431

432 Implications and Future Directions

433 This study is best conceptualized as an important first step highlighting that new 434 machine learning analytic techniques can be used to infer AD-NC traits based on 435 clinical measures collected in older adults. Further studies are still needed to determine 436 if repeated inferred levels of AD-NC traits inform on trajectories of the accumulation of 437 these different AD-NC traits. Currently, the temporal course of accumulation of these 438 different AD-NC traits and the onset of their associations with impaired cognition are 439 unknown. Such data are crucial to determine if inferred AD-NC traits could be used to 440 assess the ongoing clinical course of Alzheimer's disease, and to assess the efficacy of

J. Yang 21

441	guiding treatments targeting specific AD-NC traits. For example, separate therapies
442	have been under study for targeting the peptide amyloid- eta in extracellular amyloid
443	plaques and the protein tau in intracellular neurofibrillary tangles [7-9].
444	The analytic approach implemented in this study might also be extended to infer
445	the presence of other pathologies that are hard to measure in living adults and untangle
446	the effects of mixed-brain pathologies underlying late-life cognitive impairment and
447	dementia. Since many older adults with ADD show mixed-brain pathologies [57], further
448	work will be needed to develop analytic approaches that can infer and account for the
449	presence of different combinations of varied AD/ADRD pathologies.
450	Brain imaging as well as serum or fluid biomarkers were not examined in this
451	study, which could be used to validate the inferred levels of AD-NC traits by using our
452	developed imputation models. Additionally, the brain imaging and fluid biomarkers might
453	be included as additional predictors to enhance the imputation accuracy of AD-NC
454	traits, which could be crucial for untangling the relative contributions of mixed-brain
455	pathologies driving ADD in aging adults.
456	
457	Limitations and Strengths of this Study

This study still has several limitations. First, participants were predominantly Americans of European descent and have higher than average levels of education, so our findings will need to be replicated in more diverse populations. Second, the current study used diverse clinical predictors, many of that might not be available outside the research setting such as the composite cognition score based on 19 cognitive tests designed for ROS/MAP studies. Further work is needed to identify a parsimonious set of

J. Yang 22

464	clinical predictors that are more widely available to enhance the use of this approach in
465	diverse populations and geographic locations. Despite these limitations, this study is
466	best conceptualized as an important first step highlighting the potential of using machine
467	learning methods to infer AD-NC traits or other AD/ADRD pathologies based on clinical
468	measures that can be collected via remote phenotyping or electronic health records.
469	Nonetheless, this study has several strengths that lend confidence for the current
470	findings. All subjects were recruited from the community, underwent an annual detailed
471	clinical evaluation, and were without dementia based on their clinical assessment at

472 study entry. Large numbers of men and women underwent annual assessments, and

473 follow-up rates were very high (~90%) with an average of 8 years follow up. Uniform

and structured procedures were employed for the collection of clinical measures and

475 postmortem AD-NC traits in both MAP and ROS cohorts. An important strength of the

476 current study design is that we developed imputation models in MAP cohorts, and then

477 evaluated model performance in the second independent ROS cohort that employed

478 similar staff and data collection procedures [58].

479

J. Yang 23

481 **ACKNOWLEGEMENTS**

- 482 We are deeply indebted to all participants who contributed their data and agreed to
- 483 autopsy at the time of their death. We thank the Rush Alzheimer's Disease Center staff
- 484 for their efforts.

485

486 FUNDING

- 487 This work was supported by the National Institute of Health R35GM138313,
- 488 P30AG10161, P30AG72975, K01AG054700, R01AG15819, R01AG17917,
- 489 R01AG56352; R01AG79133, the Illinois Department of Public Health; and the Robert C.
- 490 Borwell Endowment Fund. The funding organizations had no role in the design or
- 491 conduct of the study; collection, management, analysis, or interpretation of the data; or
- 492 preparation, review, or approval of the manuscript.

493

494 **CONFLICT OF INTEREST**

- 495 Jingjing Yang is an Editorial Board Member of this journal, but was not involved in the
- 496 peer-review process nor had access to any information regarding its peer-review. There
- 497 are no other disclosures nor conflict of interest for any of the authors.

498

499 CONSENT STATEMENT

- 500 Both MAP and ROS studies were approved by an Institutional Review Board of Rush
- 501 University Medical Center. All participants agreed to annual clinical evaluations and

J. Yang 24

- autopsy at the time of death. Written informed consent was obtained from all study
- 503 participants as was an Anatomical Gift Act for organ donation.

504

505 DATA AVAILABILITY

- 506 All data analyzed in this study are de-identified and available to any qualified
- 507 investigator by submitting a request through the Rush Alzheimer's Disease Center
- 508 Research Resource Sharing Hub, <u>https://www.radc.rush.edu</u>, which has descriptions of
- 509 the studies and available data.

511 **REFERENCES**

512 [1] Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, 513 Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, 514 Trojanowski JQ, Vinters HV, Montine TJ (2012) National Institute on Aging–Alzheimer's 515 Association guidelines for the neuropathologic assessment of Alzheimer's disease. 516 Alzheimer's and Dementia 8, 1-13. 517 Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer's [2] 518 disease. Lancet 377, 1019-1031. 519 Jack CR, Jr., Albert M, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, [3] 520 Phelps CH (2011) Introduction to revised criteria for the diagnosis of Alzheimer's 521 disease: National Institute on Aging and the Alzheimer's Association workgroup. 522 Alzheimers Dement 7, 256-262. 523 [4] Wilson RS, Wang T, Yu L, Bennett DA, Boyle PA (2020) Normative Cognitive Decline in 524 Old Age. Ann Neurol 87, 816-829. 525 Boyle PA, Yu L, Leurgans SE, Wilson RS, Brookmeyer R, Schneider JA, Bennett DA (2019) [5] 526 Attributable risk of Alzheimer's dementia attributed to age-related neuropathologies. 527 Ann Neurol 85. 114-124. 528 [6] Yu L, Wang T, Wilson RS, Leurgans S, Schneider JA, Bennett DA, Boyle PA (2019) 529 Common age-related neuropathologies and yearly variability in cognition. Ann Clin 530 Transl Neurol 6, 2140-2149. 531 Zhang Y, Chen H, Li R, Sterling K, Song W (2023) Amyloid beta-based therapy for [7] 532 Alzheimer's disease: challenges, successes and future. Signal Transduct Target Ther 8, 533 248. 534 [8] Gotz J, Ittner A, Ittner LM (2012) Tau-targeted treatment strategies in Alzheimer's 535 disease. Br J Pharmacol 165, 1246-1259. 536 [9] Lee HE, Lim D, Lee JY, Lim SM, Pae AN (2019) Recent tau-targeted clinical strategies for 537 the treatment of Alzheimer's disease. Future Med Chem 11, 1845-1848. 538 Lan MJ, Ogden RT, Kumar D, Stern Y, Parsey RV, Pelton GH, Rubin-Falcone H, Pradhaban [10] 539 G, Zanderigo F, Miller JM, Mann JJ, Devanand DP (2017) Utility of Molecular and 540 Structural Brain Imaging to Predict Progression from Mild Cognitive Impairment to 541 Dementia. J Alzheimers Dis 60, 939-947. 542 Lu M, Pontecorvo MJ, Devous MD, Sr., Arora AK, Galante N, McGeehan A, Devadanam C, [11] 543 Salloway SP, Doraiswamy PM, Curtis C, Truocchio SP, Flitter M, Locascio T, Devine M, 544 Zimmer JA, Fleisher AS, Mintun MA (2021) Aggregated Tau Measured by Visual 545 Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of 546 Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 547 Phase III Clinical Trials. JAMA Neurol 78, 445-453. 548 Skillbäck T, Kornhuber J, Blennow K, Zetterberg H, Lewczuk P (2019) Erlangen Score [12] 549 Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of 550 Alzheimer's Disease. J Alzheimers Dis 69, 551-559. [13] 551 Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, Chai X, Proctor NK, 552 Eichenlaub U, Zetterberg H, Blennow K, Reiman EM, Stomrud E, Dage JL, Hansson O 553 (2020) Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers,

554		differential diagnosis, neuropathology and longitudinal progression to Alzheimer's
555		dementia. <i>Nat Med 26,</i> 379-386.
556	[14]	Ansari A, Maffioletti E, Milanesi E, Marizzoni M, Frisoni GB, Blin O, Richardson JC, Bordet
557		R, Forloni G, Gennarelli M, Bocchio-Chiavetto L (2019) miR-146a and miR-181a are
558		involved in the progression of mild cognitive impairment to Alzheimer's disease.
559		<i>Neurobiol Aging</i> 82 , 102-109.
560	[15]	Faura J, Bustamante A, Penalba A, Giralt D, Simats A, Martínez-Sáez E, Alcolea D, Fortea
561		J, Lleó A, Teunissen CE, van der Flier WM, Ibañez L, Harari O, Cruchaga C, Hernández-
562		Guillamón M, Delgado P, Montaner J (2020) CCL23: A Chemokine Associated with
563		Progression from Mild Cognitive Impairment to Alzheimer's Disease. J Alzheimers Dis 73,
564		1585-1595.
565	[16]	Silbert LC, Howieson DB, Dodge H, Kaye JA (2009) Cognitive impairment risk: white
566		matter hyperintensity progression matters. <i>Neurology</i> 73, 120-125.
567	[17]	Greene SJ, Killiany RJ (2010) Subregions of the inferior parietal lobule are affected in the
568		progression to Alzheimer's disease. Neurobiol Aging 31 , 1304-1311.
569	[18]	Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process
570		in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70,
571		960-969.
572	[19]	Pettigrew C, Soldan A, Wang J, Wang MC, Greenberg B, Albert M, Moghekar A, Team BR
573		(2022) Longitudinal CSF Alzheimer's disease biomarker changes from middle age to late
574		adulthood. Alzheimers Dement (Amst) 14, e12374.
575	[20]	Johnson KA, Fox NC, Sperling RA, Klunk WE (2012) Brain imaging in Alzheimer disease.
576		Cold Spring Harb Perspect Med 2 , a006213.
577	[21]	Ghirelli A, Tosakulwong N, Weigand SD, Clark HM, Ali F, Botha H, Duffy JR, Utianski RL,
578		Buciuc M, Murray ME, Labuzan SA, Spychalla AJ, Pham NTT, Schwarz CG, Senjem ML,
579		Machulda MM, Baker M, Rademakers R, Filippi M, Jack CR, Jr., Lowe VJ, Parisi JE,
580		Dickson DW, Josephs KA, Whitwell JL (2020) Sensitivity-Specificity of Tau and Amyloid β
581		Positron Emission Tomography in Frontotemporal Lobar Degeneration. Ann Neurol 88,
582		1009-1022.
583	[22]	Soleimani-Meigooni DN, Iaccarino L, La Joie R, Baker S, Bourakova V, Boxer AL, Edwards
584		L, Eser R, Gorno-Tempini ML, Jagust WJ, Janabi M, Kramer JH, Lesman-Segev OH,
585		Mellinger T, Miller BL, Pham J, Rosen HJ, Spina S, Seeley WW, Strom A, Grinberg LT,
586		Rabinovici GD (2020) 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease
587		and other neurodegenerative diseases. Brain 143, 3477-3494.
588	[23]	Jack CR, Jr., Holtzman DM (2013) Biomarker modeling of Alzheimer's disease. Neuron
589		80 , 1347-1358.
590	[24]	Darst BF, Lu Q, Johnson SC, Engelman CD (2019) Integrated analysis of genomics,
591		longitudinal metabolomics, and Alzheimer's risk factors among 1,111 cohort
592		participants. Genet Epidemiol 43, 657-674.
593	[25]	Chételat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, van de Giessen E, Agosta
594		F, Barkhof F, Brooks DJ, Carrillo MC, Dubois B, Fjell AM, Frisoni GB, Hansson O, Herholz
595		K, Hutton BF, Jack CR, Jr., Lammertsma AA, Landau SM, Minoshima S, Nobili F, Nordberg
596		A, Ossenkoppele R, Oyen WJG, Perani D, Rabinovici GD, Scheltens P, Villemagne VL,

597		Zetterberg H, Drzezga A (2020) Amyloid-PET and (18)F-FDG-PET in the diagnostic
598		investigation of Alzheimer's disease and other dementias. Lancet Neurol 19, 951-962.
599	[26]	Isaacs JD, Boenink M (2020) Biomarkers for dementia: too soon for routine clinical use.
600		Lancet Neurol 19 , 884-885.
601	[27]	Bălașa AF, Chircov C, Grumezescu AM (2020) Body Fluid Biomarkers for Alzheimer's
602		Disease-An Up-To-Date Overview. Biomedicines 8, 421.
603	[28]	Hastie T, Tibshirani R, Friedman J (2009) The elements of statistical learning: prediction,
604		inference and data mining. Springer-Verlag, New York.
605	[29]	Feng X, Chen L, Wang Z, Li SC (2020) I-Impute: a self-consistent method to impute single
606		cell RNA sequencing data. BMC Genomics 21, 618.
607	[30]	Li WV, Li JJ (2018) An accurate and robust imputation method scImpute for single-cell
608		RNA-seq data. Nat Commun 9, 997.
609	[31]	Gamazon ER, Wheeler HE, Shah KP, Mozaffari SV, Aquino-Michaels K, Carroll RJ, Eyler
610		AE, Denny JC, Nicolae DL, Cox NJ, Im HK (2015) A gene-based association method for
611		mapping traits using reference transcriptome data. <i>Nat Genet</i> 47 , 1091-1098.
612	[32]	Nguyen M, He T, An L, Alexander DC, Feng J, Yeo BTT (2020) Predicting Alzheimer's
613		disease progression using deep recurrent neural networks. <i>Neuroimage</i> 222 , 117203.
614	[33]	Nagpal S, Meng X, Epstein MP, Tsoi LC, Patrick M, Gibson G, De Jager PL, Bennett DA,
615		Wingo AP, Wingo TS, Yang J (2019) TIGAR: An Improved Bayesian Tool for
616		Transcriptomic Data Imputation Enhances Gene Mapping of Complex Traits. Am J Hum
617		Genet 105 , 258-266.
618	[34]	Luningham JM, Chen J, Tang S, De Jager PL, Bennett DA, Buchman AS, Yang J (2020)
619		Bayesian Genome-wide TWAS Method to Leverage both cis- and trans-eQTL Information
620		through Summary Statistics. Am J Hum Genet 107 , 714-726.
621	[35]	Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA (2018) Religious
622		Orders Study and Rush Memory and Aging Project. J Alzheimers Dis 64, S161-S189.
623	[36]	Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE (2004) Neurofibrillary tangles
624		mediate the association of amyloid load with clinical Alzheimer disease and level of
625		cognitive function. Arch Neurol 61, 378-384.
626	[37]	Bennett DA, Wilson RS, Schneider JA, Evans DA, Aggarwal NT, Arnold SE, Cochran EJ,
627		Berry-Kravis E, Bienias JL (2003) Apolipoprotein E epsilon4 allele, AD pathology, and the
628		clinical expression of Alzheimer's disease. Neurology 60, 246-252.
629	[38]	Bennett DA, Wilson RS, Schneider JA, Evans DA, Mendes De Leon CF, Arnold SE, Barnes
630		LL, Bienias JL (2003) Education modifies the relation of AD pathology to level of
631		cognitive function in older persons. <i>Neurology</i> 60 , 1909-1915.
632	[39]	Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA (2012) Relation of
633		neuropathology to cognition in persons without cognitive impairment. Ann Neurol 72,
634		599-609.
635	[40]	(1997) Consensus recommendations for the postmortem diagnosis of Alzheimer's
636		disease. The National Institute on Aging, and Reagan Institute Working Group on
637		Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.
638		Neurobiol Aging 18 , S1-2.

639 640	[41]	Wilson RS, Boyle PA, Yu L, Barnes LL, Sytsma J, Buchman AS, Bennett DA, Schneider JA
040		(2015) Temporal course and pathologic basis of unawareness of memory loss in
041 642	[40]	dementia. Neurology 85 , 984-991. Royle DA, Wilcon DS, Agganwal NT, Tang V, Bennatt DA (2006) Mild cognitive
642	[42]	boyle PA, Wilson RS, Aggarwal NT, Tang Y, Berniett DA (2006) Wild Cognitive
043		impairment: risk of Alzheimer disease and rate of cognitive decline. <i>Neurology</i> 67 , 441-
644	[40]	445.
645	[43]	WICKNANN GIVI, KNOPMAN DS, CHEFTKOW H, HYMAN BT, JACK CR, Jr., KAWAS CH, KIUNK WE,
646		Korosnetz WJ, Maniy JJ, Mayeux R, Mons RC, Morris JC, Rossor MN, Scheitens P, Carillo
64/		MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to
648		Alzheimer's disease: Recommendations from the National Institute on Aging and the
649		Alzheimer's Association workgroup. Alzheimers Dement.
650	[44]	Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS
651		(2006) Neuropathology of older persons without cognitive impairment from two
652		community-based studies. Neurology 66, 1837-1844.
653	[45]	Zou H, Hastie T (2005) Regularization and variable selection via the elastic net. <i>Journal of</i>
654		the Royal Statistical Society: Series B (Statistical Methodology) 67 , 301-320.
655	[46]	Tibshirani R (1996) Regression Shrinkage and Selection via the Lasso. Journal of the
656		Royal Statistical Society. Series B (Methodological) 58 , 267-288.
657	[47]	Hoerl AE, Kennard RW (2000) Ridge Regression: Biased Estimation for Nonorthogonal
658		Problems. <i>Technometrics</i> 42 , 80-86.
659	[48]	Linden A (2006) Measuring diagnostic and predictive accuracy in disease management:
660		an introduction to receiver operating characteristic (ROC) analysis. J Eval Clin Pract 12,
661		132-139.
662	[49]	Cox DR (1972) Regression models and life-tables. Journal of the Royal Statistical Society:
663		Series B (Methodological) 34 , 187-202.
664	[50]	Gerds TA, Scheike TH, Andersen PK (2012) Absolute risk regression for competing risks:
665		interpretation, link functions, and prediction. Stat Med 31 , 3921-3930.
666	[51]	Ozenne B, Sørensen AL, Scheike T, Torp-Pedersen C, Gerds TA (2017) riskRegression:
667		predicting the risk of an event using Cox regression models. The R Journal 9 , 440-460.
668	[52]	Powell MR, Smith GE, Knopman DS, Parisi JE, Boeve BF, Petersen RC, Ivnik RJ (2006)
669		Cognitive measures predict pathologic Alzheimer disease. Arch Neurol 63, 865-868.
670	[53]	Dickerson BC, Sperling RA, Hyman BT, Albert MS, Blacker D (2007) Clinical prediction of
671		Alzheimer disease dementia across the spectrum of mild cognitive impairment. Arch
672		Gen Psychiatry 64 , 1443-1450.
673	[54]	Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Thibodeau SN, Kokmen E,
674		Waring SC, Kurland LT (1995) Apolipoprotein E status as a predictor of the development
675		of Alzheimer's disease in memory-impaired individuals. JAMA 273, 1274-1278.
676	[55]	Bondi MW, Salmon DP, Galasko D, Thomas RG, Thal LJ (1999) Neuropsychological
677	[]	function and apolipoprotein E genotype in the preclinical detection of Alzheimer's
678		disease. Psychol Aging 14, 295-303.
679	[56]	Phongpreecha T, Cholerton B, Bukhari S, Chang AL. De Francesco D. Thuraiappah M.
680	[-•]	Godrich D. Perna A. Becker MG. Ravindra NG. Espinosa C. Kim Y. Berson E. Mataraso S.
681		Sha SJ, Fox EJ, Montine KS, Baker LD, Craft S, White L, Poston KL, Beecham G,

J. Yang 29

682		Aghaeepour N, Montine TJ (2023) Prediction of neuropathologic lesions from clinical
683		data. Alzheimers Dement 19, 3005-3018.
684	[57]	Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account
685		for most dementia cases in community-dwelling older persons. Neurology 69, 2197-
686		2204.
687	[58]	Licher S, Yilmaz P, Leening MJG, Wolters FJ, Vernooij MW, Stephan BCM, Ikram MK,
688		Ikram MA (2018) External validation of four dementia prediction models for use in the
689		general community-dwelling population: a comparative analysis from the Rotterdam
690		Study. <i>Eur J Epidemiol</i> 33 , 645-655.

J. Yang 30

692 Figure Legends

693 Fig 1. Overall study design to develop and validate imputation models that infer 694 AD-NC traits based on clinical measures in older adults. A multi-stage analytic 695 approach was employed to develop, validate, and demonstrate the effectiveness of 696 inferred levels of four AD-NC traits derived from clinical measures as AD biomarkers. A. 697 We trained imputation models for four AD-NC traits using clinical data obtained at the last 698 visit before death in MAP decedents that underwent autopsy (Fig 2). Then we validated 699 these models in an independent cohort study (ROS) that collected the same clinical and 700 postmortem measures, **B**. We tested the effectiveness as AD biomarkers for the inferred 701 levels of four AD-NC traits at baseline, which were obtained by applying the validated 702 imputation models to clinical measures obtained at study entry. We examined if the 703 inferred baseline AD-NC traits predicted incident ADD (Fig 3) and discriminated adults at 704 risk for postmortem (on average 8 years after baseline) pathologic AD in ROS cohort (Fig 705 4).

Fig 2. Machine learning methods were used to select different combinations of

707 clinical measures to infer each of the four AD-NC traits. GLM-EN method was used

to train an imputation model for each of the four AD-NC traits. Standardized effect sizes

- (beta) of selected predictive predictors with |beta| > 0.01 for each of the four imputation
- models were plotted. The inferred values of each of the inferred AD-NC traits are
- determined by the weighted averages of the corresponding selected predictors, with
- weights given by estimated standard effect sizes. Although all four AD-NC traits are
- inter-related and share cognition and *APOE E4* allele as important predictors, different
- sets of selected predictors by their imputation models highlight that different
- combinations of clinical measures with different effect sizes are necessary for inferring
 the unique features of these inter-related AD-NC traits.
- 717

718 Fig 3. Inferred baseline AD-NC traits predicted incident Alzheimer's Disease 719 **Dementia (ADD).** We used Cox proportional hazard models to examine the predictivity of each of the inferred baseline AD-NC traits along with age, sex, and education 720 721 covariates for incident ADD in 3 and 5 years after study entry. Top four panels show the 722 prediction accuracies (ROC plots) with each the four inferred baseline AD-NC traits in 723 adults without dementia (NCI+MCI) at study entry. Bottom four panels show prediction 724 accuracies with each of the four AD-NC traits in adults with NCI at study entry. As 725 expected for an effective AD biomarker, each of the inferred baseline AD-NC traits 726 predicted ADD.

727 Fig 4. Inferred AD-NC traits at study baseline discriminated postmortem pathologic

AD profiled at autopsy. Pathologic AD here is the binary postmortem NIA-Reagan status profiled at autopsy, with value 1 representing pathologic AD (teal boxplots) and 0 representing no pathologic AD (red boxplots). Two-sample t-test p-values are 1.4×10^{-10} for amyloid-β (A), 1.2×10^{-11} for tangles (B), 9.8×10^{-12} for global AD pathology (C), and 1.6×10^{-10} for pathologic AD (D).

Table 1. Prediction accuracy (with 95% confidence interval) and sensitivity with respect to selected risk score thresholds that ensure ~80% specificity by Cox models using a single inferred AD-NC trait. Values in this table are reflecting the Cox risk model prediction performance at one point in the ROC curves as shown in Fig 3, with corresponding risk score thresholds. Samples with predicted risk scores greater than the selected threshold were considered as Predicted Positives (incident ADD), otherwise Predicted Negatives (not developing ADD).

		Amyloid-β		Tangles		Global AD Pathology		Pathologic AD	
		Y3	Y5	Y3	Y5	Y3	Y5	Y3	Y5
NCI/MCI ->	Accuracy ^a (95% CI)	0.798 (0.773, 0.822)	0.788 (0.763, 0.813)	0.802 (0.777, 0.825)	0.795 (0.771, 0.818)	0.801 (0.775, 0.823)	0.796 (0.771, 0.819)	0.809 (0.784, 0.831)	0.803 (0.778, 0.826)
ADD	Sensitivity ^b	0.772	0.699	0.822	0.756	0.797	0.764	0.911	0.829
	Specificity ^c	0.800	0.800	0.800	0.800	0.800	0.800	0.800	0.800
NCI -> ADD	Accuracy ^a (95% CI)	0.796 (0.768, 0.823)	0.792 (0.763, 0.7819)	0.794 (0.765, 0.821)	0.791 (0.761, 0.818)	0.795 (0.767, 0.823)	0.793 (0.764, 0.820)	0.804 (0.775, 0.830)	0.805 (0.777, 0.832)
	Sensitivity ^b	0.650	0.634	0.550	0.609	0.600	0.658	0.950	0.902
	Specificity ^c	0.800	0.800	0.800	0.800	0.800	0.800	0.800	0.800

a. Accuracy= (# True Positive Predictions + # True Negative Predictions) / (# of test samples)

b. Sensitivity = (# True Positive Predictions) / (# Positives in test samples) = True Positive Fraction

c. Specificity = (# True Negative Predictions) / (# Negatives in test samples) = 1–False Positive Fraction

FIGURES

Fig 1. Overall study design to develop and validate imputation models that infer AD-NC traits based on clinical measures in older adults. A multi-stage analytic approach was employed to develop, validate, and demonstrate the effectiveness of inferred levels of four AD-NC traits derived from clinical measures as AD biomarkers. A. We trained imputation models for four AD-NC traits using clinical data obtained at the last visit before death in MAP decedents that underwent autopsy (Fig 2). Then we validated these models in an independent cohort study (ROS) that collected the same clinical and postmortem measures. B. We tested the effectiveness as AD biomarkers for the inferred levels of four AD-NC traits at baseline, which were obtained by applying the validated imputation models to clinical measures obtained at study entry. We examined if the inferred baseline AD-NC traits predicted incident ADD (Fig 3) and discriminated adults at risk for postmortem (on average 8 years after baseline) pathologic AD in ROS cohort (Fig 4).



Fig 2. **Machine learning methods were used to select different combinations of clinical measures to infer each of the four AD-NC traits.** GLM-EN method was used to train an imputation model for each of the four AD-NC traits. Standardized effect sizes (beta) of selected predictive predictors with |beta| > 0.01 for each of the four imputation models were plotted. The inferred values of each of the inferred AD-NC traits are determined by the weighted averages of the corresponding selected predictors, with weights given by estimated standard effect sizes. Although all four AD-NC traits are inter-related and share cognition and *APOE E4* allele as important predictors, different sets of selected predictors by their imputation models highlight that different combinations of clinical measures with different effect sizes are necessary for inferring the unique features of these inter-related AD-NC traits.



Fig 3. Inferred baseline AD-NC traits predicted incident Alzheimer's Disease Dementia (ADD). We used Cox proportional hazard models to examine the predictivity of each of the inferred baseline AD-NC traits along with age, sex, and education covariates for incident ADD in 3 and 5 years after study entry. Top four panels show the prediction accuracies (ROC plots) with each the four inferred baseline AD-NC traits in adults without dementia (NCI+MCI) at study entry. Bottom four panels show prediction accuracies with each of the four AD-NC traits in adults with NCI at study entry. As expected for an effective AD biomarker, each of the inferred baseline AD-NC traits predicted ADD.



Fig 4. Inferred AD-NC traits at study baseline discriminated postmortem pathologic AD profiled at autopsy. Pathologic AD here is the binary postmortem NIA-Reagan status profiled at autopsy, with value 1 representing pathologic AD (teal boxplots) and 0 representing no pathologic AD (red boxplots). Two-sample t-test p-values are 1.4×10^{-10} for amyloid- β (A), 1.2×10^{-11} for tangles (B), 9.8×10^{-12} for global AD pathology (C), and 1.6×10^{-10} for pathologic AD (D).

